Abstract
Alzheimers Disease (AD) is a progressive and degenerative neurological disorder characterized by loss of cognition and memory. However, the pathogenesis of AD is still not clearly known. Current research in drug discovery for treatment of AD involves various targets, being only symptomatic, with the main therapeutic strategies based on "cholinergic hypothesis" and "amyloid cascade hypothesis". During the last decade, inhibitors of acetylcholinesterase (AChE) such as tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®), and galanthamine (Reminyl®) have been launched. More recently, memantine (Ebixa®) has been emerged on the market as an N-methyl-D-aspartate (NMDA) receptor antagonist, which has been approved to be effective in the treatment of moderate to severe type of AD. In this review, we will focus on recent status of drug molecules for treatment of AD, currently either that in clinical practice, or still in clinical trials.
Keywords: dementia, acetylcholinesterase inhibitor, NMDA receptor, Galanthamine, Amyloid cascade hypothesis, curcumin
Letters in Drug Design & Discovery
Title: Recent Developments in Natural and Synthetic Drug Research for Alzheimers Disease
Volume: 3 Issue: 4
Author(s): Gurdal Orhan, Ilkay Orhan and Bilge Sener
Affiliation:
Keywords: dementia, acetylcholinesterase inhibitor, NMDA receptor, Galanthamine, Amyloid cascade hypothesis, curcumin
Abstract: Alzheimers Disease (AD) is a progressive and degenerative neurological disorder characterized by loss of cognition and memory. However, the pathogenesis of AD is still not clearly known. Current research in drug discovery for treatment of AD involves various targets, being only symptomatic, with the main therapeutic strategies based on "cholinergic hypothesis" and "amyloid cascade hypothesis". During the last decade, inhibitors of acetylcholinesterase (AChE) such as tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®), and galanthamine (Reminyl®) have been launched. More recently, memantine (Ebixa®) has been emerged on the market as an N-methyl-D-aspartate (NMDA) receptor antagonist, which has been approved to be effective in the treatment of moderate to severe type of AD. In this review, we will focus on recent status of drug molecules for treatment of AD, currently either that in clinical practice, or still in clinical trials.
Export Options
About this article
Cite this article as:
Orhan Gurdal, Orhan Ilkay and Sener Bilge, Recent Developments in Natural and Synthetic Drug Research for Alzheimers Disease, Letters in Drug Design & Discovery 2006; 3 (4) . https://dx.doi.org/10.2174/157018006776743215
DOI https://dx.doi.org/10.2174/157018006776743215 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Berberine Ameliorates Cognitive Impairment by Regulating Microglial Polarization and Increasing Expression of Anti-inflammatory Factors following Permanent Bilateral Common Carotid Artery Occlusion in Rats
CNS & Neurological Disorders - Drug Targets Peptidase Inhibitors as a Possible Therapeutic Strategy for Chagas Disease
Current Enzyme Inhibition Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal
Current Drug Targets Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Ultrasound Diagnostic Method in Vascular Dementia: Current Concepts
Current Medical Imaging Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Shilajit (Mumie): Current Status of Biochemical, Therapeutic and Clinical Advances
Current Nutrition & Food Science Following Intracellular Cholesterol Transport by Linear and Non-Linear Optical Microscopy of Intrinsically Fluorescent Sterols
Current Pharmaceutical Biotechnology The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study
Current Neurovascular Research An Outline of the Historical and Clinical Aspects of Catatonic Schizophrenia
Current Psychiatry Reviews Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Multi-Target Inhibitors for Proteins Associated with Alzheimer: In Silico Discovery using Fragment-Based Descriptors
Current Alzheimer Research Marine Natural Products as Acetylcholinesterase Inhibitor: Comparative Quantum Mechanics and Molecular Docking Study
Current Computer-Aided Drug Design Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets